IL-6 Test · Blood

Most people have heard of C-reactive protein, the standard blood test doctors use to check for inflammation. But CRP is a downstream product, a second-hand signal. IL-6 (interleukin-6) is the molecule that tells your liver to make CRP in the first place. When IL-6 stays elevated for months or years, it acts as a slow-burning fuse connected to heart disease, type 2 diabetes, stroke, and cancer. Measuring it gives you a window into your body's inflammatory state that is both earlier and more specific than CRP alone.

What makes IL-6 unusual is that it plays for both teams. In the short term, a spike of IL-6 after a hard workout or an infection is normal and even protective. It helps coordinate your immune response and signals your body to start repairing tissue. The problem begins when IL-6 stays chronically elevated, often due to excess body fat, persistent stress, poor sleep, or smoldering disease. That sustained signal flips from helpful to harmful, fueling the low-grade inflammation that accelerates aging and chronic disease.

What IL-6 Actually Is

IL-6 belongs to a family of immune signaling molecules called cytokines. Your immune cells (especially a type of white blood cell called macrophages), fat cells, and connective tissue cells all produce it. Once released into the bloodstream, IL-6 travels to the liver and triggers production of acute-phase proteins, including CRP, fibrinogen, and serum amyloid A. These proteins ramp up inflammation, promote blood clotting, and mobilize the immune system.

IL-6 also has a dual signaling system that determines whether it helps or hurts. In what scientists call "classical signaling," IL-6 binds to receptors on the surface of specific immune and liver cells, producing mostly protective, anti-inflammatory effects. In "trans-signaling," IL-6 binds to a free-floating version of its receptor in the blood, which then activates cells that normally would not respond to IL-6. Trans-signaling is the pathway primarily responsible for chronic, damaging inflammation.

Heart Disease Risk

The link between IL-6 and cardiovascular disease is one of the strongest and best-studied. In the Multi-Ethnic Study of Atherosclerosis (MESA), which followed over 6,600 adults without heart disease for more than 13 years, people in the highest third of IL-6 levels were about twice as likely to die from any cause compared to those in the lowest third. The risk of dying specifically from cardiovascular disease was about 55% higher, and this held true across all racial and ethnic groups studied.

The Atherosclerosis Risk in Communities (ARIC) study added an important detail: IL-6 predicted cardiovascular events independently of CRP and other standard biomarkers. In other words, IL-6 carries risk information that CRP cannot capture on its own. A meta-analysis combining data from over 24,000 people estimated that for every two standard-deviation increase in long-term IL-6 levels (after correcting for the natural day-to-day fluctuation in the number), the risk of coronary heart disease roughly doubled.

What this means for you: if your IL-6 is in the upper range, your cardiovascular risk may be higher than standard cholesterol panels suggest, especially if you are already on a statin. The MESA data showed IL-6 improved prediction of stroke and heart failure specifically among statin users, a group whose residual risk is often invisible to traditional markers.

Type 2 Diabetes

Chronic IL-6 elevation predicts the development of type 2 diabetes years before blood sugar becomes abnormal. In the Women's Health Initiative, postmenopausal women in the highest quarter of IL-6 were about three times as likely to develop diabetes compared to those in the lowest quarter. That association held even after accounting for fasting glucose and fasting insulin, meaning IL-6 was capturing risk that standard metabolic testing missed.

A meta-analysis of 10 prospective studies involving nearly 20,000 participants confirmed a dose-response relationship: for each unit increase in IL-6, the risk of developing type 2 diabetes rose by about 31%. The European EPIC-Potsdam study found a similar pattern, with the top quarter of IL-6 carrying roughly 2.6 times the diabetes risk of the bottom quarter, independent of BMI, waist-to-hip ratio, and HbA1c.

Stroke

A meta-analysis of 11 studies tracking over 27,000 people over an average of 12 years found that each standard-deviation increase in IL-6 was associated with a 19% higher risk of ischemic stroke. In the REGARDS cohort, people in the highest quarter of IL-6 had about double the stroke risk of those in the lowest quarter after adjusting for traditional stroke risk factors. That study also found that IL-6 partly explained the known disparity in stroke rates between Black and White Americans.

Cancer Associations

IL-6's connection to cancer is primarily through mortality rather than new diagnoses. In the REGARDS cohort, people with the highest IL-6 levels had roughly 13 times the cancer death rate of those with the lowest levels. The Health Aging and Body Composition study found a similar pattern: IL-6 predicted cancer death but not cancer incidence, suggesting that chronic inflammation accelerates cancer progression more than it triggers new cancers.

For specific cancer types, the evidence is strongest for lung and colon cancer. A pooled analysis of three cohorts found that former smokers in the highest quarter of IL-6 had about 2.7 times the lung cancer risk compared to the lowest quarter. For colon cancer, data from the CLUE II cohort showed that people in the upper third of IL-6 had about 2.5 times the risk.

Longevity and Aging

IL-6 is one of the most consistent blood markers linked to lifespan. A meta-analysis of nine prospective studies in older adults found that those with the highest IL-6 levels had about 49% higher all-cause mortality and 69% higher cardiovascular mortality compared to the lowest levels. The Rancho Bernardo Study, which followed older adults for a median of 15 years, found that each standard-deviation increase in IL-6 was associated with a 48% increase in death risk and, in men, about one year of shorter lifespan.

The Whitehall II study added a practical threshold: adults whose IL-6 stayed above 2.0 pg/mL on two measurements five years apart had about half the odds of aging successfully (defined as maintaining cognitive function, physical ability, and freedom from chronic disease) compared to those who stayed below that level. A 2026 Mendelian randomization study confirmed this is not just an association: genetically higher IL-6 levels are causally linked to increased mortality.

Reference Ranges

IL-6 levels can vary meaningfully depending on the assay your lab uses, your age, your body composition, and even what time of day the blood was drawn. The numbers below are drawn from multiple published studies and give you a general orientation, but you should always compare your results within the same lab over time rather than treating any single cutpoint as absolute.

A 2021 meta-analysis of 140 studies including over 12,000 healthy adults reported a pooled average of 5.2 pg/mL, with a wide range from 0 to 43.5 pg/mL. That average is higher than many individual-study reference ranges because it includes older populations and varied assay platforms. From a longevity perspective, the Whitehall II data suggests that keeping IL-6 consistently below 2.0 pg/mL is associated with the best aging outcomes. IL-6 rises by roughly 0.05 pg/mL per year of age, so ranges should be interpreted with your age in mind.

Tracking Your Trend

A single IL-6 reading is one of the least reliable snapshots in laboratory medicine. The within-person coefficient of variation (a measure of how much your level bounces around naturally) runs between 27% and 48%, meaning your IL-6 can swing by a third or more from one draw to the next without any change in your health. Research suggests you need at least two to three measurements to get a reliable picture of your true baseline.

Serial tracking is where IL-6 becomes most useful. The landmark Danesh meta-analysis found that correcting for year-to-year fluctuation roughly doubled the apparent strength of the IL-6-heart disease link. In other words, researchers were underestimating the danger because single measurements are noisy. When you track your own trend, you cut through that noise. A value that looks mildly elevated on one draw might be part of a steady upward trajectory that only becomes visible over two or three readings spaced months apart.

Get a baseline reading, then retest in three to six months if you are making lifestyle changes (weight loss, new exercise routine, dietary overhaul). Once you have established your personal range, retest at least annually. If your level is climbing, that trend matters more than any single number.

When Results Can Be Misleading

IL-6 follows a circadian rhythm, with levels peaking around 4 to 5 AM and again around 4 to 7 PM, and hitting their lowest point between 8 and 10 AM. For the most consistent results, draw your blood in the morning.

A hard workout can spike IL-6 dramatically in the hours afterward. This is a normal, healthy muscle-derived signal (called a myokine response) and does not reflect chronic inflammation. If you exercised vigorously within 24 hours of your draw, your result may be artificially high. Similarly, psychological stress, a recent illness, or surgery can push IL-6 up for days to weeks. Sepsis, for example, can drive IL-6 above 1,000 pg/mL. Even a standard meal can shift IL-6, so fasting before the draw produces the most reliable reading.

Several common medications lower IL-6 without treating an underlying inflammatory condition. Corticosteroids like dexamethasone powerfully suppress IL-6 production, so if you are taking steroids for an unrelated condition (asthma, allergies, joint pain), your IL-6 may read artificially low. GLP-1 receptor agonists (semaglutide, liraglutide) also reduce IL-6 through their anti-inflammatory effects. If you are on any of these medications, your IL-6 result reflects both your biology and the drug's effect, and you should interpret it with that in mind.

Sample handling matters more for IL-6 than for most lab tests. Delays in processing, temperature shifts during transport, or agitation of the blood sample can cause immune cells in the tube to release IL-6 after the draw, producing a falsely elevated result. If your result seems unexpectedly high, a repeat draw with careful sample handling is a reasonable next step.